Table 1.
Characteristics of full and propensity score-matched cohorts
| Characteristics | Full Cohort | Propensity Score Matched | ||||
|---|---|---|---|---|---|---|
| NAC (n=694) | Surgery (n=2183) | P value | NAC (n=413) | Surgery (n=413) | P value | |
| Gender | 0.0034* | 0.1468 | ||||
| Male | 503(72.48) | 1452(66.51) | 282(68.28) | 301(72.88) | ||
| Female | 191(27.52) | 731(33.49) | 131(31.72) | 112(27.12) | ||
| Age (years) | <0.001* | 0.8234 | ||||
| <60 | 260(37.46) | 623(28.54) | 135(32.69) | 132(31.96) | ||
| >=60 | 434(62.54) | 1560(71.46) | 278(67.31) | 281(68.04) | ||
| Age median (range) | 62(36-84) | 64(29-86) | <0.001* | 63(40-84) | 64(40-82) | 0.1178 |
| Tumour length (cm) median (range) | 6(1-19) | 4(0.5-17) | <0.001* | 5(1-19) | 5(1-17) | 0.8976 |
| BMI median (range) | 23.1(15.6-33.9) | 23.10(14.3-35.0) | 0.9888 | 23.10(15.6-33.6) | 23.30(15.6-30.9) | 0.6943 |
| NA | 183 | 170 | 114 | 34 | ||
| <18.5 | 25(4.89) | 111(5.56) | 0.7592 | 15(5.02) | 20(5.28) | 0.9584 |
| 18.5-24 | 288(56.36) | 1097(54.90) | 161(53.85) | 200(52.77) | ||
| ≥24 | 198(38.75) | 790(39.54) | 123(41.14) | 159(41.95) | ||
| Smoking | 0.0885 | 0.1674 | ||||
| NA | 167 | 66 | 102 | 13 | ||
| Never | 259(49.15) | 1153(54.46) | 169(54.34) | 189(47.25) | ||
| Ever | 66(12.52) | 231(10.91) | 40(12.86) | 57(14.25) | ||
| Current | 202(38.33) | 733(34.62) | 102(32.80) | 154(38.50) | ||
| Alcohol | 0.0568 | 0.2620 | ||||
| NA | 180 | 76 | 111 | 16 | ||
| Never | 278(54.09) | 1238(58.76) | 176(58.28) | 218(54.91) | ||
| Ever | 21(4.09) | 55(2.61) | 15(4.97) | 13(3.27) | ||
| Current | 215(41.83) | 814(38.63) | 111(36.75) | 166(41.81) | ||
| Clinical TNM staging 7th ed N (%) | <0.001* | 0.2960 | ||||
| NA | 63() | 135() | 0 | 0 | ||
| Stage I | 7(1.11) | 193(9.42) | 3(0.73) | 3(0.73) | ||
| Stage II | 303(47.94) | 1341(65.48) | 252(61.02) | 230(55.69) | ||
| Stage III | 321(50.79) | 514(25.10) | 158(38.26) | 180(43.58) | ||
| Weight (kg) median (range) | 63(38-98) | 62(34-110) | 0.0797 | 63(40-96) | 63(38-59) | 0.8791 |
| NA | 183 | 170 | 114 | 188 | ||
| Histological Grade | <0.001* | 0.7843 | ||||
| NA | 11 | 47 | 158 | 22 | ||
| G1 | 23(3.37) | 140(6.55) | 12(4.71) | 22(6.45) | ||
| G1-G2 | 60(8.78) | 318(14.89) | 34(13.33) | 45(13.20) | ||
| G2 | 180(26.35) | 666(31.18) | 104(40.78) | 125(36.66) | ||
| G2-G3 | 75(10.98) | 325(15.22) | 40(15.69) | 54(15.84) | ||
| G3 | 345(50.51) | 687(32.16) | 65(25.49) | 95(27.86) | ||
| CMI positive N (%) | 2(0.58) | 7(0.72) | 1.0000 | 2(0.91) | 2(1.14) | 1.0000 |
| pCR N (%) | 12(6.45) | NA | NA | 25(6.05) | NA | NA |
| ypTNM stage | ||||||
| I | 68(9.80) | 406(18.60) | 39(9.44) | 63(15.25) | ||
| II | 246(35.45) | 868(39.76) | 161(38.98) | 144(34.87) | ||
| III | 292(42.07) | 692(31.70) | 172(41.65) | 148(35.84) | ||
| IVA | 78(11.24) | 191(8.75) | 32(7.75) | 51(12.35) | ||
| IVB | 10(1.44) | 26(1.91) | 9(2.18) | 7(1.69) | ||
| Cycles of NAC median (Q1, Q3) | 2(1,2) | NA | NA | 2(1,2) | NA | NA |
| Cycles of NAC | NA | NA | ||||
| 1~2 | 653(94.09) | NA | 387(93.70) | NA | ||
| 3-4 | 40(5.76) | NA | 25(6.05) | NA | ||
| 5 | 1(0.14) | NA | 1(0.24) | NA | ||
| Cycles of AC median (Q1, Q3) | 2(1,2) | NA | NA | 2(1,4) | NA | NA |
| AC N (%) | 0.001* | 0.886 | ||||
| Yes | 287(41.35) | 748(34.26) | 159(38.50) | 161(38.98) | ||
| No | 407(58.65) | 1435(65.74) | 254(61.50) | 252(61.02) | ||
Abbreviations: NAC, neoadjuvant chemotherapy; N, number; BMI, body mass index; NA, not available; TNM, tumour/node/metastasis; G1, well differentiated; G2, moderately differentiated; G3, poorly differentiated; CMI, circumferential margin involvement; ypTNM, pathological tumour/node/metastasis; Q, quarter; AC, adjuvant therapy; * Statistically significant (p<0.05).